Trials / Completed
CompletedNCT00055523
A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
A Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease when compared to placebo (an inactive substance)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adalimumab (D2E7) |
Timeline
- Start date
- 2002-04-01
- First posted
- 2003-03-06
- Last updated
- 2006-08-15
Locations
43 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00055523. Inclusion in this directory is not an endorsement.